Eli Lilly Eyes $2T Valuation as Foundayo Logs 7,335 Prescriptions in Week 4
Eli Lilly could double its market cap from $920B to $2T on catalysts including late-stage weight-loss drugs eloralintide and bimagrumab, potential Alzheimer’s and oncology breakthroughs, and Nvidia AI supercomputer partnership. Meanwhile, its oral obesity pill Foundayo reached 7,335 U.S. prescriptions in its fourth week, indicating uptake relative to rival Wegovy.
1. Potential $2 Trillion Valuation
Eli Lilly’s market capitalization stands at $920B after retreating from a $1T peak; major growth drivers include expansion of its weight-loss drug portfolio, clinical breakthroughs in Alzheimer’s and oncology, and productivity improvements from an Nvidia AI supercomputer partnership that could support a $2T valuation.
2. Weight-Loss Pipeline Advances
Late-stage weight-loss candidates eloralintide and bimagrumab aim to extend Lilly’s GLP-1 leadership, while ongoing Alzheimer’s and oncology trials seek to broaden therapeutic offerings and revenue diversification.
3. Foundayo Prescription Trends
Foundayo, the company’s new oral obesity treatment, logged 7,335 U.S. prescriptions in its fourth week, a modest rate compared with competitor programs that underscores intensifying market competition.